HOWL — Werewolf Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1785530 ·
Last close
$1.05
Market Cap
$51.03M
52W High
$1.20
52W Low
$0.27
ADV30
400,435
Next earnings
2026-11-16
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -10,054,000 -9,877,000 42,753,000 41,870,000 35,994,000
Jun 2026 21,000,000 — 7,158,000 3,670,000 24,155,000 21,987,000 7,863,000
Mar 2026 0 — -13,271,000 -13,532,000 58,022,000 46,450,000 45,820,000
Dec 2025 0 — -9,418,000 -8,381,000 69,396,000 57,050,000 44,591,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-30,148,000
Investing CF
$0
Financing CF
$6,028,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.76
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-485,272,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-30,060,000
Pretax Income TTM
$-34,613,000
Interest Exp TTM
$4,553,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$21,000,000
EBITDA
$-21,921,000
Free Cash Flow
$-12,233,750
Enterprise Value
$25,654,664
Total Cash
$21,987,000
Total Debt
$0
Shares Out
48,599,066
Trailing EPS
$-0.73
Book Value
$0.34
ROE
-119.9%
ROA
-27.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -60,677,000 -60,822,000 69,396,000 44,591,000 24,805,000 -60,292,000
Dec 2024 1,885,000 -73,594,000 -70,515,000 126,929,000 53,539,000 73,390,000 -56,188,000
Dec 2023 19,943,000 -40,503,000 -37,368,000 174,833,000 63,459,000 111,374,000 -32,612,000
Dec 2022 16,401,000 -56,056,000 -53,810,000 160,245,000 37,908,000 122,337,000 -40,596,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$1,971,000
NetIncome TTM
$-34,613,000
OpCashFlow TTM
—
Assets (Latest)
$24,155,000
Forward EPS
$-0.59

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.00 · spot: $1.03 · call volume: 10 · put volume: 32
Expected Move to 2027-04-16: ±$0.95 (92.23%) — implied range $0.08 – $1.98 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MIST Milestone Pharmaceuticals Inc. $51.44M $0.41 —
ONCY ONCOLYTICS BIOTECH INC $50.15M $0.38 —
PDSB PDS Biotechnology Corp $50.03M $0.89 —
AZR Azora Therapeutics, Inc. (DE) $52.36M $3.66 —
SPRO Spero Therapeutics, Inc. $52.51M $0.90 —

News headlines (Yahoo Finance, 1h cache)

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
2026-11-09 13:30 · Yahoo
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
2026-10-30 12:30 · Yahoo
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
2026-10-13 15:00 · Yahoo
New Strong Buy Stocks for October 9th
2026-10-09 09:46 · Yahoo
1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost
2026-08-26 15:47 · Yahoo
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News
2026-08-21 17:51 · Yahoo
Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing
2026-08-21 13:26 · Yahoo
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
2026-08-21 12:00 · Yahoo
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
2026-07-31 11:00 · Yahoo
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
2026-05-07 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.